Terry Fox Research Institute
11
6
7
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
9%
1 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
Role: collaborator
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
Role: collaborator
Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy
Role: collaborator
Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)
Role: collaborator
MRI-Guided Ultrasound Stimulated Microbubbles Radiation Treatment for Patients with Chest-Wall and Locally Advanced Breast Cancer
Role: collaborator
Novel Magnetic Resonance Imaging-Guided Ultrasound-Stimulated Microbubble Radiation Treatment for Patients With Chest-Wall and Breast Cancer
Role: collaborator
MRI-Guided Focused Ultrasound Radiosensitization for Patients With Malignant Melanoma and Non Melanoma Skin Cancer
Role: collaborator
AML-MDS Novel Prognostic Tests Clinical Study
Role: collaborator
Study to Identify Mechanisms of Resistance to Standard Therapy in Patients With Metastatic Colorectal Cancer
Role: collaborator
Fluorescent Visualization in Early Oral Cancer
Role: collaborator
Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL
Role: collaborator
All 11 trials loaded